Explore the latest books of this year!
Bookbot

Acute Myeloid Leukemia

Book rating

Parameters

  • 366 pages
  • 13 hours of reading

More about the book

This book, written by a team of leading experts, provides a comprehensive overview of acute myeloid leukemia (AML), the most frequent acute leukemia in adults. The opening chapters present current knowledge of epidemiology, etiologic factors, and the pathogenesis and molecular development of AML. Detailed guidance is offered on laboratory and clinical diagnostic workup and disease classification, and the patient- and disease-related factors that determine prognosis and treatment allocation are identified. On the basis of these general considerations, initial treatments in patients considered fit for intensive treatment and in older and co-morbid patients are reviewed, and the available relapse treatment strategies, explained. For all clinical scenarios, the most recent data on the optimal use of newly approved agents in different AML subgroups are presented. Separate chapters address the treatment of acute promyelocytic leukemia, current practice of allogeneic stem cell transplantation, and special clinical situations. Finally, promising approaches in drug development, current standards and challenges in assessment of measurable residual disease, immune approaches, and ideas for innovative trial designs are considered.

Book purchase

Acute Myeloid Leukemia, Gert J. Ossenkoppele, Christoph Röllig

Language
Released
2021
product-detail.submit-box.info.binding
(Hardcover)
We’ll email you as soon as we track it down.

Payment methods

2.0
Mixed feelings
1 Ratings

We’re missing your review here.

Title
Acute Myeloid Leukemia
Language
English
Publisher
Springer
Released
2021
Format
Hardcover
Pages
366
ISBN10
3030726754
ISBN13
9783030726751
Series
Rating
2 out of 5
Description
This book, written by a team of leading experts, provides a comprehensive overview of acute myeloid leukemia (AML), the most frequent acute leukemia in adults. The opening chapters present current knowledge of epidemiology, etiologic factors, and the pathogenesis and molecular development of AML. Detailed guidance is offered on laboratory and clinical diagnostic workup and disease classification, and the patient- and disease-related factors that determine prognosis and treatment allocation are identified. On the basis of these general considerations, initial treatments in patients considered fit for intensive treatment and in older and co-morbid patients are reviewed, and the available relapse treatment strategies, explained. For all clinical scenarios, the most recent data on the optimal use of newly approved agents in different AML subgroups are presented. Separate chapters address the treatment of acute promyelocytic leukemia, current practice of allogeneic stem cell transplantation, and special clinical situations. Finally, promising approaches in drug development, current standards and challenges in assessment of measurable residual disease, immune approaches, and ideas for innovative trial designs are considered.